

Andy Hill Cancer Research Endowment Standing Committee on Grants Meeting Minutes January 11, 2023

The following board members appointed by the CARE Fund Board of Directors currently comprise the Standing Committee on Grants: Cliff Berkman, Thomas Brown, David Byrd, and Karin Rodland.

Committee Members Present and Constituting a Quorum: Cliff Berkman, Thomas Brown, David Byrd, Karin Rodland

Committee Members Absent: None

CARE Staff Attendees: Laura Flores Cantrell, Peter Choi, Tasha Florez, Jennifer Puttuck

Guest Attendees: None

Wednesday, January 11, 2023, 10:00–11:00 a.m. (PT)

1. Welcome

Karin Rodland welcomed the Committee members and thanked them for their participation.

Karin reminded the Committee that the CARE Fund Statute (RCW 43.348.050) states that an independent expert scientific review and advisory committee for the purpose of evaluating grant proposals for cancer research and recommending grants to be made from the CARE Fund must be appointed by the Board. The committee must consist of individuals with nationally recognized expertise in the scientific, clinical, ethical, commercial, and regulatory aspects of cancer research, prevention, and care.

Peter Choi said that the reviewer panels for Breakthrough Seed Funding (listed on the agenda) are not ready and Breakthrough Seed Funding reviewers will be discussed in a future Committee meeting.

2. Appoint Scientific Review Committee Members

Karin invited the Committee to disclose any affiliations, or actual, potential, or perceived conflicts of interest. No conflicts of interest were identified.

Due to the large number of applications to the Life Science Start-Up and Development Requests for Proposals, three review panels focused on specific scientific or technological themes will be used.

a. Life Science Start-Up Development Panel 1 – Detection, Treatment, and Development

Karin verified that the Committee had an opportunity to adequately review the project summaries as well as the American Institute of Biological Sciences (AIBS) reviewer candidates' information. She opened the floor for Committee discussion of the reviewer candidates.

Committee members raised questions regarding whether there was sufficient business/start-up expertise represented on Panel 1.

The Committee proposed requesting that CARE Fund staff ask AIBS if it was feasible to provide additional expertise on commercial start-up activities for Life Science Start-Up and Development Panel 1 by having either additional input from reviewers with relevant expertise from Life Science Start-Up and Development Panel 2 or staff members within AIBS provide this expertise in coordination with the Panel 1 review panel Chair.

MOTION: Thomas Brown moved to appoint the slate of reviewer candidates to the scientific review committee as presented by AIBS to review the Life Science Start-Up and Development Panel 1 applications with the addendum that CARE Fund staff ask AIBS to obtain expertise on start-ups and early-stage commercialization efforts either from reviewers with relevant expertise from Panel 2 for Life Science Start-Up and Development or from AIBS staff in coordination with the review panel Chair. David Byrd seconded the motion. The motion was approved unanimously.

b. Life Science Start-Up and Development Panel 2 – Manufacturing

Karin provided a brief overview of the AIBS reviewer candidates' areas of expertise. She opened the floor for Committee discussion of the reviewer candidates. There were no concerns with the candidates' qualifications as presented.

MOTION: Thomas Brown moved to appoint the slate of reviewer candidates to the scientific review committee as presented by AIBS to review the Life Science Start-Up and Development Panel 2 applications. David Byrd seconded the motion. The motion was approved unanimously.

c. Life Science Start-Up and Development Panel 3 – Targeted Cellular Therapeutics

Karin provided a brief overview of the AIBS reviewer candidates' areas of expertise. She opened the floor for Committee discussion of the reviewer candidates. There were no concerns with the candidates' qualifications as presented.

MOTION: David Byrd moved to appoint the slate of reviewer candidates to the scientific review committee as presented by AIBS to review the Life Science Start-Up and Development Panel 3 applications. Thomas Brown seconded the motion. The motion was approved unanimously.

d. Shared Resources and Infrastructure

Peter provided the project summary for Shared Resources and Infrastructure proposal 4 in PowerPoint through the shared screen on the Zoom meeting. This project summary was inadvertently not included in the meeting materials provided in advance of the meeting.

Karin provided a brief overview of the AIBS reviewer candidates' areas of expertise. She opened the floor for Committee discussion of the reviewer candidates. There were no concerns with the candidate's qualifications as presented.

MOTION: Cliff Berkman moved to appoint the slate of reviewer candidates to the scientific review committee as presented by AIBS to review the Shared Resource and Infrastructure applications. Thomas Brown seconded the motion. The motion was approved unanimously.

e. <u>Inclusion and Diversity in Cancer Clinical Trials and Population Health</u>

Karin provided a brief overview of the AIBS reviewer candidates' areas of expertise. She opened the floor for Committee discussion of the reviewer candidates.

A discussion followed. A concern was raised that there are no physicians or clinical trialists included in this panel. The Committee agreed to Laura Flores Cantrell's suggestion to have CARE Fund staff request that AIBS endeavor to include more physicians on future panels.

MOTION: David Byrd moved to appoint the slate of reviewer candidates to the scientific review committee as presented by AIBS to review the Inclusion and Diversity in Cancer Clinical Trials and Population Health applications. Cliff Berkman seconded the motion. The motion was approved unanimously.

3. Appoint Breakthrough Seed Funding Grant Application Review Committee Members

This information is not yet available, and this agenda item is postponed to a future meeting.

4. Award Decision Process

Tasha Florez presented the draft schematic of the award decision process for Committee review and feedback.

A discussion followed. Tasha will include the Committee's feedback in an updated draft to present to the full Board at the February 22, 2023 Board meeting.

5. Public Comment

No members of the public were present to provide comment.

7. Adjourn

With no other business, the meeting was adjourned at 11:04 a.m.

I certify that the foregoing is a true and correct copy of the minutes approved by the CARE Board of Directors at a regular meeting of the board on February 22, 2023.

Eunice Hostetter Eunice Hostetter (Feb 26, 2023 11:41 PST)	02/26/2023